Tratamiento de la colitis ulcerosa fulminante refractaria con anticuerpos quiméricos anti-CD25
暂无分享,去创建一个
[1] B. Sandhu,et al. Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease , 2010, Journal of pediatric gastroenterology and nutrition.
[2] J. Fell,et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. , 2010, Journal of pediatric gastroenterology and nutrition.
[3] C. Salinas,et al. Eficacia y seguridad de tacrolimus oral para el tratamiento de la enfermedad inflamatoria intestinal pediátrica , 2009 .
[4] V. V. Calderón,et al. Infliximab como terapia de rescate en colitis ulcerosa grave resistente al tratamiento corticoideo , 2008 .
[5] E. Ceriati,et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis , 2007, Langenbeck's Archives of Surgery.
[6] N. Shepherd,et al. Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease , 2006, Alimentary pharmacology & therapeutics.
[7] J. Markowitz,et al. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. , 2006, Journal of pediatric gastroenterology and nutrition.
[8] M. Dubinsky,et al. Severe Colitis in Children , 2005, Journal of pediatric gastroenterology and nutrition.
[9] R. Storb,et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] M. Malago',et al. Efficacy and tolerability of interleukin‐2 receptor blockade with basiliximab in pediatric renal transplant recipients , 2001, Pediatric transplantation.